Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0893 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MK-0893 + Sitagliptin | EXPERIMENTAL | - |
| MK-0893 + Metformin | EXPERIMENTAL | - |
| Sitagliptin + Metformin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MK-0893 | DRUG | Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks). |
| Sitagliptin | DRUG | Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks). |
| Metformin | DRUG | Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks). |
| Placebo for MK-0893 | DRUG | Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period. |
| Placebo for Sitagliptin | DRUG | Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks). |
| Placebo for Metformin | DRUG | Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks). |
Inclusion Criteria: * Participants who have Type 2 Diabetes Mellitus, with suboptimal glucose control, while either not on AHA (antihyperglycemic agent) therapy or on monotherapy or on low-dose combination therapy Exclusion Criteria: * Participants have a history of Type 1 Diabetes Mellitus * Par...
MK-0893 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It has been studied in clinical trials for its glucose-lowering effects, both alone and in combination with other diabetes medications. The drug is not approved and remains in clinical development.
MK-0893 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The company has sponsored multiple clinical trials evaluating the drug's safety and efficacy in patients with Type 2 Diabetes Mellitus.
MK-0893 has completed Phase 1 and Phase 2 clinical trials. The most advanced studies are Phase 2 trials, which have been completed. The drug is investigational and has not received FDA approval. It is not currently in active clinical development according to available trial records.
MK-0893 has been studied in three completed clinical trials. These include NCT00631488, a Phase 2 study of MK-0893 in combination with other diabetes drugs; NCT00902161, a Phase 1 single-dose crossover study; and NCT02004886, a Phase 2 study assessing safety and glucose-lowering efficacy. All trials have been completed.
MK-0893 is a small molecule designed to lower blood glucose levels in patients with Type 2 Diabetes Mellitus. The specific molecular target has not been disclosed in the available clinical trial information. The drug has been evaluated for its effects on glucose metabolism in multiple clinical studies.
MK-0893 is a distinct investigational compound developed by Merck. It has been studied in combination with other diabetes medications, but it is not the same as those drugs. No alternative names for MK-0893 have been reported in the clinical trial records.